Barry Bunin

Inside CDD Vault, A Different Kind of Silicon Valley Success Story

Behind the Code: the Human Side of Collaborative Drug Discovery

• Broschiertes Buch

Produktbeschreibung

Inside CDD Vault takes readers into a different kind of Silicon Valley story--one balancing long-term growth with a mission catalyzing scientific progress for the greater good. Go deep into the hearts of the people helping scientists discover new medicines. Told through the personal journeys of team members--from executives to engineers to scientists--this book reveals the human stories behind the software, the values that shape the company's unusual path. From the emotional weight of personal loss to the practical triumphs of global collaboration, Inside CDD Vault is a story of trauma, resilience, and meaning. It's about building a business that's both for-profit and for-purpose.

Produktdetails

• Verlag: Collaborative Drug Discovery, Inc.
• Seitenzahl: 176
• Erscheinungstermin: 15. November 2025
• Englisch
• Abmessung: 229mm x 152mm x 12mm
• Gewicht: 387g
• ISBN-13: 9798993644301
• Artikelnr.: 75913981

Autorenporträt

Barry A. Bunin, Ph.D. is the CEO of Collaborative Drug Discovery. Dr. Bunin has overseen $100 million in business transactions over the last two decades. Prior to CDD, he was an Entrepreneur in Residence with Eli Lilly & Co. Dr. Bunin is on a patent for Kyprolis¿ (Carfilzomib for Injection) - a selective proteasome inhibitor that received accelerated FDA approval for the treatment of patients with multiple myeloma that was widely viewed as the centerpiece of Amgen's $10.4 Billion acquisition of Onyx Pharmaceuticals.Dr. Bunin was the founding CEO, President, & CSO of Libraria (now Eidogen-Sertanty). At Libraria, he led a team that integrated exhaustive reaction capture (synthetic chemistry) with gene-family wide SAR capture (medicinal chemistry). On the scientific side, he co-authored "Chemoinformatics: Theory, Practice, and Products" (Springer-Verlag), a text that overviews modern chemoinformatics technologies, and "The Combinatorial Index" (Academic Press), a widely used text on high-throughput chemical synthesis. In the lab, Dr. Bunin did medicinal synthetic chemistry developing patented new chemotypes for protease inhibition at Axys Pharmaceuticals (now Celera) and RGD mimics to inhibit GP-IIbIIIa at Genentech. Dr. Bunin received his B.A. from Columbia University and his Ph.D. from UC Berkeley, where he synthesized and tested the initial 1,4-benzodiazepine libraries with Professor Jonathan Ellman.